Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Mode of Hysterectomy After FDA Morcellation Advisory

Obstet Gynecol; ePub 2017 May 5; Ottarsdottir, et al

Overall rate of minimally invasive surgery declined at a single institution from 2013 to 2015 following the FDA’s recommendations and morcellation guidelines release, although key perioperative outcomes remained similar, a recent study found. The retrospective study reviewed all patients who underwent a hysterectomy for benign indications at Brigham and Women’s Hospital from 2013 to 2015. Rates of abdominal, vaginal, laparoscopic, and robotic-assisted laparoscopic hysterectomy as well as the perioperative outcomes were compared over the study period. Researchers found:

  • 1,530 patients underwent a hysterectomy for benign indications and 639 underwent the procedure for the indication of uterine leiomyomas.
  • There was a 40% to 60% decreased odds of a minimally invasive procedure in 2014 or 2015 compared with 2013, in patients with leiomyomas alone.
  • A 24% decrease in the supracervical approach to hysterectomy was also observed.
  • However, the majority of cases in each year were still performed in a minimally invasive fashion.

Citation:

Ottarsdottir H, Cohen SL, Cox M, Vitonis A, Einarsson JI. Trends in mode of hysterectomy after the U.S. Food and Drug Administration power morcellation advisory. [Published online ahead of print May 5, 2017]. Obstet Gynecol. doi:10.1097/AOG.0000000000002058.